{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"D.Bil.,decrease to low,n=30"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"D.Bil., to normal or no change,n=30"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"D.Bil.,increase to high,n=30"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Chloride,decrease to low,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Chloride, to normal or no change,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Chloride,increase to high,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"CO2,decrease to low,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"CO2, to normal or no change,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"CO2,increase to high,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"LDH,decrease to low,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"LDH, to normal or no change,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"LDH,increase to high,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"T.Pro,decrease to low,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"T.Pro, to normal or no change,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"T.Pro,increase to high,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"BUN,decrease to low,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"BUN, to normal or no change,n=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"BUN,increase to high,n=35"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, T.Pro and BUN. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data for worst-case post Baseline is presented.","groups":[{"description":"Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).","id":"OG000","title":"Part 2: GSK2857916 3.40 mg/kg (MM)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)","title":"Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)","type":"PRIMARY","unitOfMeasure":"Participants"}